Scully Timothy G, Roberts Louise, Dinh Diem, Brennan Angela, Clark David, Ajani Andrew, Reid Christopher M, Oqueli Ernesto, Hiew Chin, Stub Dion, Chandrasekhar Jaya, Freeman Melanie
Department of Cardiology, Eastern Health, Box Hill, VIC, Australia.
Department of Cardiology, Eastern Health, Box Hill, VIC, Australia.
Cardiovasc Revasc Med. 2025 Aug;77:97-101. doi: 10.1016/j.carrev.2024.10.008. Epub 2024 Oct 28.
Embolic protection devices were developed to reduce the risk of common complications encountered during percutaneous coronary intervention (PCI) of saphenous vein grafts, however, in the setting of contemporary multi-modality medical management, their overall efficacy has been called into question. This study aimed to assess the evolving utilization and clinical outcomes associated with distal filter wire embolic protection devices in saphenous vein PCI.
Consecutive patients undergoing PCI to a saphenous vein graft in a registry were included. Peri-procedural and long-term outcomes including 12-month mortality and 30-day MACCE rates were compared between PCI using a distal filter wire embolic protection device and unprotected PCI.
From 2005 to 2020, a total of 753 patients underwent PCI to a saphenous vein graft with 256 using a distal filter wire embolic protection device. At one year, the use of a distal filter wire embolic protection devices was not associated with a decrease in mortality (4.7 % vs 5.4 %, p = 0.19) and there was no difference in 30-day MACCE rates between protected and unprotected saphenous vein PCI (3.1 % vs 5.8 %, p = 0.10).
In this 12-month analysis of saphenous vein graft PCI, there was no evidence that distal filter wire embolic protection devices improved short term post procedural or long-term mortality outcomes.
栓子保护装置旨在降低隐静脉搭桥经皮冠状动脉介入治疗(PCI)期间常见并发症的风险,然而,在当代多模式医疗管理背景下,其总体疗效受到质疑。本研究旨在评估隐静脉PCI中远端滤器导丝栓子保护装置的使用变化情况及临床结局。
纳入登记处接受隐静脉搭桥PCI的连续患者。比较使用远端滤器导丝栓子保护装置的PCI与未使用该装置的PCI的围手术期和长期结局,包括12个月死亡率和30天主要不良心血管事件(MACCE)发生率。
2005年至2020年,共有753例患者接受隐静脉搭桥PCI,其中256例使用远端滤器导丝栓子保护装置。一年时,使用远端滤器导丝栓子保护装置与死亡率降低无关(4.7%对5.4%,p = 0.19),且受保护与未受保护的隐静脉PCI的30天MACCE发生率无差异(3.1%对5.8%,p = 0.10)。
在这项对隐静脉搭桥PCI的12个月分析中,没有证据表明远端滤器导丝栓子保护装置能改善术后短期或长期死亡率结局。